Downregulation of miR-9 correlates with poor prognosis in colorectal cancer
- Abstract
- Introduction: microRNAs (miRNAs) are frequently dysregulated in many human cancers including colorectal cancer (CRC) and are useful candidate biomarkers in liquid biopsy of cancer for their stability in the blood.
Methods: We compared the expression of microRNA-9 (miR-9) in tissues (n = 357) and sera (n = 109) of CRC patients to determine whether miR-9 in serum reflects that in the cancer tissue in parallel. Also, we examined the miR-9 role in CRC by in vitro functional studies in four CRC cell lines.
Results: On multivariate analysis of colorectal cancer tissues and sera, miR-9 low expressions were significantly associated pN stage (tissues; p < 0.01, serum; p = 0.013), and clinical stage (tissues; p < 0.01, serum; p = 0.031). Moreover, patients with low miR-9 expression had shorter survival than those with high miR-9 expression (log-rank test, tissue; p = 0.021, serum; p = 0.011). miR-9 level in serum reflects that in the tumor. The CRC cells with low miR-9 expression was significantly increased cell proliferation, migration, invasion and colony formation than cells with high miR-9 expression.
Conclusion: Serum miR-9 is an useful early detection marker in liquid biopsy of CRC and overexpression of miR-9 in CRC may be a novel prognostic marker as well.
- All Author(s)
- H. Kim
; T. Kim
; G. Jaygal
; J. Woo
; C. J. Kim
; M. J. Baek
; D. Jeong
- Issued Date
- 2020
- Type
- Article
- Keyword
- Colorectal cancer; Liquid biopsy; Marker; miR-9; miRNA inhibitor; miRNA mimic
- Publisher
- European Society of Pathology
- ISSN
- 0344-0338
; 1618-0631
- Citation Title
- Pathology, research and practice
- Citation Volume
- 216
- Citation Number
- 8
- Citation Start Page
- 153044
- Citation End Page
- 153044
- Language(ISO)
- eng
- DOI
- 10.1016/j.prp.2020.153044
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2595
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.